Eisai Pharmaceuticals India Pvt. Ltd (“Eisai India”), a leading Japanese pharmaceutical company in India, announced today that it has commenced sales of Biogen’s multiple sclerosis (MS) portfolio in India based on a collaboration agreement between Eisai India’s parent company Eisai Co., Ltd. (“Eisai”) and Biogen Inc. (“Biogen”)for India and other Asian countries.
Under the agreement, Eisai distributes and books sales for Biogen’s MS treatments,AVONEX® (interferon beta 1a), TYSABRI® (natalizumab), TECFIDERA® (dimethyl fumarate)and PLEGRIDY® (peginterferon beta-1a) in India.
The number of MS patients has increased in India in recent years. No survey has been done for MS Patients, but it is estimated that there are about ~200,000 MS patients in India. MS is being increasingly diagnosed due to an increase in the number of practicing neurologists and easy and affordable availability of magnetic resonance imaging (MRI).
“Abiding by our core philosophy of human health care and access to medicine, we strive to work in areas of unmet medical needs and make available the support needed by patients and their families for coping with the disease. MS is one such unmet disease segment and providing the patients with necessary support, we can significantly improve the quality of life of patients and give them hope to live a better life,” …